[1] SU ZY, SIAK PY, LWIN YY, Et al. Epidemiology of nasopharyngeal carcinoma: current insights and future outlook
[J]. Cancer Metastasis Rev,2024,43(3):919-939. 

[2] ZHANG R, HE Y, WEI B, et al. Nasopharyngeal Carcinoma Burden and Its Attributable Risk Factors in China: Estimates and Forecasts from 1990 to 2050
[J]. Int J Environ Res Public Health,2023;20(4):2926.

[3] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会（CSCO）鼻咽癌诊疗指南2025
[M].北京:人民卫生出版社,2025:135-141.

[4] 中国抗癌协会,鼻咽癌专业委员会. 中国肿瘤整合诊治指南（CACA）鼻咽癌
[EB/OL].(2025-01-10)
[2025-11-17].https://cacaguidelines.cacakp.com/pdflist/detail?id=409.

[5] HO-FUN LEE V. Approaching a cure for nasopharyngeal carcinoma: how close are we from there?
[J]. Lancet Reg Health West Pac,2024,50:101186.

[6] 张伟,任丽丽,江超,等.全程局部同步推量调强放疗治疗局部晚期食管癌的效果及对3年生存率的影响
[J].临床误诊误治,2023,36(1):41-44.

[7] 陆冬云,羊剑,孙锦意,等.不同部位食管癌实施直线加速器调强适形放射治疗的临床剂量学评价
[J].中国医药导报.2023(20):125-128.

[8] 张煜婕,陈杰,陈涵波,等.调强放疗时代诱导化疗在Ⅱ~Ⅳa期鼻咽癌中的研究进展
[J].肿瘤学杂志.2020, 26(4): 289-294.

[9] YIN WJ, MAO W, YANG F, et al. Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions
[J]. Oral Oncol,2024,158:107001.

[10] YOU R, LIU YP, XIE YL, et al. Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
[J]. Lancet. 2023, 401(10380):917-927. 

[11] KILLOCK D. Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes
[J]. Nat Rev Clin Oncol,2023,20(5):283.

[12] 中国抗癌协会鼻咽癌专业委员会,林少俊,陈晓钟,等.复发鼻咽癌治疗专家共识
[J].中华放射肿瘤学杂志,2018, 27(1):16-22.

[13] LIAO S, ZHANG B, SU Y, et al. Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma: A prospective multicenter phaseⅡtrial
[J]. Strahlenther Onkol, 2024, 200(10):867-875.

[14] DE CREVOISIER R, LAFOND C, MERVOYER A, et al. Image-guided radiotherapy
[J]. Cancer Radiother,2022, 26(1-2):34-49.

[15] 王喆,魏硕,王澜霏.TRILOGY直线加速器的锥形束CT在鼻咽癌放射治疗图像引导过程中的摆位误差分析
[J].医学理论与实践,2025,38(21):3662-3664.

[16] CHIANG YW, LIAO LJ, WU CY, et al. Spotted Temporal Lobe Necrosis following Concurrent Chemoradiation Therapy Using Image-Guided Radiotherapy for Nasopharyngeal Carcinoma
[J]. Case Rep Otolaryngol, 2022, 2022:5877106.

[17] LIANG X, MOHAMMADI H, MORENO KC, et al. Heavy Ion Particle Therapy in Modern Day Radiation Oncology
[J]. Hematol Oncol Clin North Am,2025,39(2):377-397. 

[18] ZHANG A, FAN L, LIU Q, et al. Immunological Effects of Proton Radiotherapy: New Opportunities and Challenges in Cancer Therapy
[J]. Cancer Innov,2025,4(2):e70003.

[19] JANG JY, KIM K, CHEN MF, et al. A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy
[J]. Cancer Med, 2024,13(3):e7023. 

[20] YAHYA N, MOHAMAD SALLEH SA, MOHD NASIR NF, et al. Toxicity profile of patients treated with proton and carbon-ion therapy for primary nasopharyngeal carcinoma: A systematic review and meta-analysis
[J]. Asia Pac J Clin Oncol,2024,20(2):240-250. 

[21] LI Y, GUAN X, XING X, et al. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis
[J]. Head Neck,2024,46(7):1766-1776.

[22] HUNG HM, CHAN OCM, MAK CH, et al. Dosimetric comparison of intensity modulated radiotherapy and intensity modulated proton therapy in the treatment of recurrent nasopharyngeal carcinoma
[J].Med Dosim,2022, 47(1):14-19. 

[23] WU PW, HUANG CC, CHANG PH, et al. Post-irradiation Sinus Mucosa Disease in Nasopharyngeal Carcinoma Patients Treated With Proton Therapy
[J]. Laryngoscope, 2025,135(6):1908-1914.

[24] PRESS RH, MEHTA MP. Proton Therapy: Current Status and Controversies
[J]. JCO Oncol Pract,2024,20(6):747-749.

[25] LI G, XIA YF, HUANG YX, et al. Intensity-modulated proton radiation therapy as a radical treatment modality for nasopharyngeal carcinoma in China: Cost-effectiveness analysis
[J]. Head Neck,2022,44(2):431-442.

[26] LI G, QIU B, HUANG YX, et al. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China
[J]. BMC Cancer,2020,20(1):599.

[27] ZHENG M, WANG S, ZHU Y, et al. Trajectories of fear of progression in nasopharyngeal carcinoma patients receiving proton and heavy ion therapy
[J]. Support Care Cancer,2023,31(12):630.

[28] ZHENG M, WANG S, ZHU Y, et al. A qualitative exploration of fear of progression in patients with nasopharyngeal carcinoma treated with proton and heavy ion therapy
[J]. Support Care Cancer,2023,31(12):622.

[29] XU M, YANG S, CUI E, et al. Induction chemotherapy for nasopharyngeal carcinoma
[J]. BMJ,2025,389:r652.

[30] WU Q, LI S, LIU J, et al. Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis
[J]. Eur Arch Otorhinolaryngol,2022,279(11):5057-5069.

[31] WANG BC, KUANG BH, LIU XX, et al. Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis
[J]. Front Oncol,2022,12:927510.

[32] TANG LL, CHEN L, XU GQ, et al. Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial. CA Cancer J Clin. 2025,75(3):203-215.

[33] LI Q, ZHAO YH, XU C, et al. Chemotherapy-Induced Senescence Reprogramming Promotes Nasopharyngeal Carcinoma Metastasis by circRNA-Mediated PKR Activation
[J]. Adv Sci (Weinh),2023,10(8):e2205668.

[34] XU YC, CHEN KH, Liang ZG, Zhu XD. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma
[J]. Front Oncol,2022,12:843675.

[35] TANG LL, GUO R, ZHANG N, et al. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial
[J]. JAMA,2022,328(8):728-736. 

[36] ZHAO X, TIAN L, CHEN Y, et al. Long-term outcomes of induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study
[J]. Front Oncol,2024,14:1475176.

[37] XIE WH, XIAO WW, CHANG H, Et al. Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial
[J]. BMJ,2025,389:e081557. 

[38] HUANG PY, CHEN XY, DING X, et al. Induction versus Concurrent Chemotherapy for Advanced Nasopharyngeal Carcinoma
[J]. NEJM Evid. 2025,4(5):EVIDoa2400214. 

[39] DAI J, ZHANG B, SU Y, et al. Induction Chemotherapy Followed by Radiotherapy vs Chemoradiotherapy in Nasopharyngeal Carcinoma: A Randomized Clinical Trial
[J]. JAMA Oncol,2024,10(4):456-463.

[40] YU JM, CHANG CL, LIN KC, et al. Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyn-geal Cancer
[J]. J Natl Compr Canc Netw,2024,22(9): e247046. 

[41] LIU X, ZHANG Y, YANG KY, et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
[J]. Lancet, 2024,403(10445):2720-2731.

[42] YIP PL, LEE AWM, CHUA MLK. Adjuvant chemotherapy in nasopharyngeal carcinoma
[J]. Lancet Oncol,2023,24(7): 713-715.

[43] LIU Y, LI Y, HOU Y, et al. LIU Y combined with concurrent chemoradiotherapy enhances survival rates in cases of locally advanced nasopharyngeal carcinoma
[J]. Am J Cancer Res,2024,14(6):3142-3152.

[44] LIU LT, LIU H, HUANG Y, et al. Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial
[J]. Lancet Oncol,2023, 24(7):798-810.

[45] MIAO J, WANG L, TAN SH, et al. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial
[J]. JAMA oncology,2022,8(12), 1776-1785.

[46] Cheng, H., Chen, J., Li, Y., et al. Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma
[J]. British journal of cancer,2025,133(1),85-93.

[47] HUANG H, YAO Y, DENG X, et al. Immunotherapy for nasopharyngeal carcinoma: Current status and prospects
[J]. Int J Oncol,2023,63(2):97.

[48] MANAKO T, YASUMATSU R, NAKANO T, et al. Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
[J]. In Vivo, 2023,37(2):747-755. 

[49] XU R, WONG CHL, CHAN KSK, et al. PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials
[J]. Front Oncol,2024, 14:1386381. 

[50] GUVEN DC, STEPHEN B, SAHIN TK, et al. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis
[J]. Laryngoscope,2024,134(1):7-17.

[51] Yan X, Chen S, Dai G, et al. Efficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis
[J]. Tumori,2025,111(1):88-99.

[52] YU Z, HONG S, YU H, et al. Efficacy and safety of immune checkpoint inhibitors in the treatment of recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis
[J]. Chin Med J (Engl),2025, 138(5):531-539.

[53] LUO J, XIAO W, HUA F, et al. Efficacy and safety of PD-1 inhibitors in recurrent or metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens: a systematic review and meta-analysis
[J].BMC Cancer,2023,23(1):1172.

[54] SUN H, BU F, LI L, et al. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials
[J]. Ann Pharmacother, 2024,58(4):349-359.

[55] DAI Z, LI N, WANG J, et al. Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
[J]. Front Pharmacol, 2023,14:1212813.

[56] LOOI CK, LOO EM, LIM HC, Et al. Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies
[J]. Front Immunol,2024,15: 1484535.

[57] OKAFOR S, MUZAFFAR J, JANG D, et al. Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy
[J]. J Neurol Surg Rep,2023,84(3):e113-e115.

[58] HOPKINS R, XIANG W, MARLIER D, et al. Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma
[J]. Mol Ther,2021,29(2):734-743.

[59] HUO Q, LV J, ZHANG J, et al. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma
[J]. Cytotherapy,2023,25(10):1037-1047. 

[60] HONG X, WANG G, XU G, et al. Prognostic value of EGFR and p-EGFR in nasopharyngeal carcinoma: A systematic review and meta-analysis
[J]. Medicine (Baltimore),2022,101(3):e28507.

[61] SUN W, LONG G, WANG J, et al. Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: a meta-analysis
[J]. Head Neck,2014,36(10): 1508-1516. 

[62] ZENG T, XIAO D, ZHU W, et al. ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance
[J]. Mol Cancer Ther,2025,24(10):1611-1625.

[63] AN Z, HE L, CHEN T, et al. The efficacy and safety of EGFR-TKI in recurrent/metastatic nasopharyngeal carcinoma patients: A systematic review and meta-analysis
[J]. Laryngoscope Investig Otolaryngol,2024, 9(3):e1279.

[64] NIU X, LIU P, ZHOU X, et al. Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with chemoradiotherapy for induction chemotherapy resistant locally advanced nasopharyngeal carcinoma: A prospective phase II study
[J]. Transl Oncol.,2024,39: 101797.

[65] QIU MZ, ZHANG Y, GUO Y, et al. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial
[J]. JAMA Oncol,2022,8(7):1042-1046. 

[66] MA Y, HUANG Y, ZHAO Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
[J]. Lancet Oncol,2024,25(7):901-911. 

[67] FEI Z, XU T, HONG H, et al. PET/CT standardized uptake value and EGFR expression predicts treatment failure in nasopharyngeal carcinoma
[J]. Radiat Oncol,2023,18(1):33. 

[68] XU Y, QUAN Z, ZHAN Y, et al. SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma
[J]. J Clin Pathol,2024,77(12): 829-834.

[69] LAM RCT, HUI CWC, WONG CH, et al. Preclinical evaluation of the VEGF/Ang2 bispecific nanobody BI 836880 in nasopharyngeal carcinoma models
[J]. Invest New Drugs, 2023,41(5):699-709.

[70] ZHU Y, HU Y, YANG C, et al. Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma
[J]. Curr Mol Pharmacol, 2024,17:e18761429290933.

[71] SUN X, ZHU Y, LOU Y, et al. Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis
[J]. Eur Arch Otorhinolaryngol,2024,281(8):3929-3941.

[72] LEE NY, HARRIS J, KIM J, et al. Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma: A Nonrandomized Controlled Trial
[J]. JAMA Netw Open,2023,6(6): e2316094.

[73] CHONG WQ, LOW JL, TAY JK, et al. Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial
[J]. Lancet Oncol, 2025, 26(2):175-186.

[74] YU J, DU X, ZHANG S, et al. Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation
[J]. Mol Ther Oncol,2024,32(3):200858. 

[75] PENG L, WANG Y, LUO J, et al. miR-128-3p increases the radiosensitivity in nasopharyngeal carcinoma via regulating vascular endothelial growth factor C
[J]. Pathol Res Pract,2023,249:154768.

[76] LU N, JIANG YF, XIA WX, et al. Efficacy and safety of sintilimab plus bevacizumab in metastatic nasopharyngeal carcinoma after failure of platinum-based chemotherapy: an open-label phase 2 study
[J]. EClinicalMedicine, 2023,62:102136.